GlassScriptPhysician profile
Bill G Bell
NPI 1194913988
$62,373.56
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $16K · 2021: $1,473 · 2022: $1,695 · 2023: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $38,166.47 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14,116.42 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $2,815.03 | 2019-2022 | |
| Bausch Health US, LLC | $2,440.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $607.20 | 2019-2020 | |
| Oyster Point Pharma, INC. | $567.89 | 2022 | |
| Dompe US, INC. | $473.95 | 2021-2022 | |
| Allergan, INC. | $470.75 | 2019-2021 | |
| Shire North American Group INC | $441.94 | 2019 | |
| Alcon Vision LLC | $418.14 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $367.56 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $273.34 | 2023 | Xipere |
| Mallinckrodt Hospital Products INC. | $253.69 | 2020-2022 | |
| Rxsight INC | $234.07 | 2022 | |
| Maculogix, INC. | $177.35 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $171.25 | 2020-2023 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $136.13 | 2020-2021 | |
| Beaver-Visitec International, INC. | $102.70 | 2019 | |
| Optos, INC. | $57.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.65 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.61 | 2019 | |
| Abbvie INC. | $18.73 | 2022 | |
| Notal Vision, INC. | $17.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.